KEGG   DRUG: NivolumabHelp
Entry
D10316                      Drug                                   

Name
Nivolumab (USAN/INN);
Nivolumab (genetical recombination) (JAN);
Opdivo (TN)
Product
Formula
C6362H9862N1712O1995S42
Exact mass
143509.1148
Mol weight
143597.3811
Sequence
(Heavy chain)
QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV IWYDGSKRYY
ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND DYWGQGTLVT VSSASTKGPS
VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS
VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT
VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE MTKNQVSLTC
LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV
MHEALHNHYT QKSLSLSLGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(dimer)
(disulfide bridges: H22-H96, H127-L214, H140-H196, H219-H'219, H222-H'222, H254-H314, H360-H418, H'22-H'96, H'127-L'214, H'140-H'196, H'254-H'314, H'360-H'418, L-23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Remark
Therapeutic category: 
ATC code: 
Chemical group: 
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  Disease
Melanoma [DS:H00038]
Non-small cell lung cancer [DS:H00014]
Renal cell carcinoma [DS:H00021]
Hodgkin lymphoma [DS:H00007]
Comment
Monoclonal antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC17 Nivolumab
      D10316  Nivolumab (USAN/INN)
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Nivolumab
    D10316  Nivolumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10316  Nivolumab (USAN/INN); Nivolumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD279
    Nivolumab
     D10316  Nivolumab (USAN/INN)
Antineoplastics [br08340.html]
 D10316
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10316
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10316
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10316
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10316
Orphan drugs in the USA [br08355.html]
 Orphan drugs in the USA
  D10316
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
 Companion diagnostics
  D10316
BRITE hierarchy
Other DBs
CAS: 
946414-94-4
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system